Tag : Eisai

Latest News

Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval

Newsemia
FOSTER CITY, Calif. & TOKYO–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) announced today that Gilead Sciences K.K. (Tokyo, Japan) and...
Latest News

Defying analyst expectations, Eisai launches study of a-beta drug BAN 2401 in Alzheimer’s

Newsemia
After Thursday’s halt to aducanumab’s development dealt a significant blow to the amyloid beta hypothesis in Alzheimer’s, analysts had expected BAN 2401 – developed under...
Neurology

Eisai enters into agreement with Eurofarma for its anti-obesity agent lorcaserin

Newsemia
Eisai Co., Ltd. has entered into an agreement to grant exclusive development and marketing rights for its anti-obesity agent lorcaserin hydrochloride in Brazil to Eurofarma...
Latest News

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Newsemia
Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer’s Disease meeting, in Barcelona, Spain, from the recent 36-...
Neurology

Eisai: EC approves marketing of LENVIMA as first-line treatment for hepatocellular carcinoma

Newsemia
Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the...
Cardiology

Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Grafting: Trends in Utilization and Propensity-Matched Analysis of In-Hospital Outcomes [Structural Heart Disease]

Newsemia
Background—A significant proportion of patients requiring aortic valve replacement (AVR) have undergone prior coronary artery bypass grafting (CABG). Reoperative heart surgery is associated with increased...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy